Acquiry Labs · Hidden Acquisitions Index

https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/ · Data v1.0, 17 November 2026

NVIDIA – Recursion Pharmaceuticals

  • Investment and partnership
  • Related deal
  • AI layer: foundation models
  • Buyer worth over US$100 billion
  • United States

The deal in brief

Showing facts with an official source only.

Recursion Pharmaceuticals works on foundation models for biology and drug discovery.

NVIDIA and Recursion Pharmaceuticals agreed an investment and partnership (opens in a new tab).

NVIDIA invested US$50 million (opens in a new tab) in Recursion Pharmaceuticals.

NVRPNVIDIARecursion PharmaceuticalsBuyerCompanyInvested US$50 million
NVRPNVIDIARecursion PharmaceuticalsBuyerCompanyInvested US$50 million
Deal diagram for NVIDIA and Recursion Pharmaceuticals. From NVIDIA to Recursion Pharmaceuticals: invested US$50 million.

Key facts

Announced
12 July 2023
Value
US$50 million

In the source’s words

“NVIDIA invested $50 million in Recursion via a private placement”
RecursionA · Official source Read it in context (opens in a new tab)Archived copy (opens in a new tab)

“to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery”

What the buyer received

No public record of: licence, exclusive licence, board seat, observer, veto, exclusivity, right of first refusal, consultation, compute commitment.

Deals with the same terms

About Recursion Pharmaceuticals

What it does
Foundation models for biology and drug discovery.
Country
United States

One amount, as the source states it

Regulators and advisers

Notification thresholds at the time
  • HSR general size tests: Holdings valued above USD 111.4m are subject to the size-of-person test through USD 445.5m. One person must generally have USD 22.3m and the other USD 222.7m in annual net sales or total assets under the statutory tests. Above USD 445.5m the size-of-person test drops out. Exemptions and commerce rules remain relevant. Source (opens in a new tab)

Advisers

10 sources, grouped by what they prove

The deal terms (3)

  1. RecursionA · Official source29 February 2024
    “priority access”
  2. RecursionA · Official source12 July 2023
    “to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery”
  3. RecursionA · Official source29 February 2024
    “NVIDIA invested $50 million in Recursion”

Money (3)

  1. RecursionA · Official source12 July 2023
    “$50 million investment by NVIDIA”
  2. RecursionA · Official source
    “NVIDIA invested $50 million in Recursion via a private placement”
  3. Latham & WatkinsA · Official source12 July 2023
    “Latham & Watkins Advises NVIDIA on Investment in Recursion Pharmaceuticals”

Dates (1)

  1. RecursionA · Official source12 July 2023
    “July 12, 2023 at 8:30 AM EDT”
Background checks (3): identity, address, headquarters and AI-business test
  1. SECA · Official source
    “"city":"SANTA CLARA","stateOrCountry":"CA"”
  2. RecursionA · Official source29 February 2024
    “Salt Lake City, Utah”
  3. NVIDIA Corporation (Form 10-K cover page)A · Official source29 July 2022

    Form 10-K, aggregate market value held by non-affiliates

    “as of July 29, 2022 was approximately $434.37 billion”

Similar deals

NVIDIA’s other deals

NVIDIA and Emerald AI

Investment and partnership

NVIDIA and Emerald AI, Inc. agreed an investment and partnership.

NVIDIA and Lancium

Investment and partnership

NVIDIA invested. Lancium’s AI factory campuses were designated as deployment sites for NVIDIA’s full-stack computing platform.

Continued

Other deals with the same structure

ASML and Mistral AI

Investment and partnership

ASML and Mistral AI agreed an investment and partnership.

Continued

KDDI and Sakana AI

Investment and partnership

KDDI and Sakana AI agreed an investment and partnership.

Continued

Alibaba and Moonshot AI

Investment and partnership

Alibaba disclosed a minority preferred stake.

Alibaba invested about US$800 million in Moonshot AI.

Cite and download

Cite this deal

APA

Boyton, J. (2026). NVIDIA – Recursion Pharmaceuticals (2023). In The Hidden Acquisitions Index (Version 1.0). Acquiry Labs. https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/ (checked 2026-11-16)

BibTeX

@misc{hai_nvidia_recursion_2023,
  author = {Boyton, Joash},
  title = {NVIDIA – Recursion Pharmaceuticals (2023)},
  howpublished = {The Hidden Acquisitions Index, Acquiry Labs},
  version = {1.0},
  year = {2026},
  url = {https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/},
  note = {Checked 2026-11-16}
}

Bluebook

Joash Boyton, NVIDIA – Recursion Pharmaceuticals (2023), The Hidden Acquisitions Index (Acquiry Labs, version 1.0, 2026), https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/ (last visited 16 November 2026).

Plain text

NVIDIA – Recursion Pharmaceuticals (2023). The Hidden Acquisitions Index, Acquiry Labs, version 1.0. https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/. Checked 2026-11-16.

Short attribution

according to the Hidden Acquisitions Index (Acquiry Labs)
Download

The journalist pack has this deal as CSV, the share card in four sizes, every source with its quote, and a note on how to credit it.

Correct this record

Announced 12 July 2023 · Sources checked 16 Nov 2026 · Data v1.0

Acquiry Labs, a research division of Acquiry Pty Ltd

“Hidden” means the transaction is not classified as an acquisition in conventional M&A statistics. It does not mean secret, unlawful or intentionally concealed. Inclusion makes no claim about any party’s motive or the legality of any transaction.

Acquiry Labs is the research division of Acquiry Pty Ltd, a Melbourne M&A advisory firm. The Index uses no confidential client information, accepts no paid placement and charges no fees. Transactions on which Acquiry has advised are excluded.

Data version v1.0 · as of 17 November 2026